Please ensure Javascript is enabled for purposes of website accessibility

Why Exelixis, Inc. Shares Slumped Today

By Todd Campbell - Jul 1, 2015 at 6:21PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Exelixis Inc.'s FDA review for approval of cobimetinib has been delayed until November.

What's Happening: Shares in Exelixis (EXEL 0.57%) slumped by 10% earlier today and closed 7% down after the company reported that the FDA is delaying a decision regarding approval of its cobimetinib, a therapy for BRAF V600 mutation-positive advanced melanoma.

Why it's happening: The FDA was expected to weigh in with a decision on whether or not to approve cobimentib in August, but the agency's new timeline means that investors won't know its decision until November 11.

The delay is reportedly in order to provide a reasonable amount of time to review additional information from Exelixis' CoBRIM trial, as requested by the regulator. The CoBRIM trial evaluated cobimetinib and Zelboraf as a co-therapy alternative to Zelboraf monotherapy.

Exelixis developed cobimetinib internally; however, it licensed cobimetinib to Roche's Genentech, the maker of Zelboraf, in 2006.

Since cobimetinib is out-licensed, Exelixis won't reap the full benefit -- or endure the full pain -- of an FDA go or no go decision. However, investors are eager for Exelixis to deliver a win following the failure of its once-promising Cometriq in a late stage prostate cancer trial.

If the FDA review of this additional information goes smoothly and an approval is granted, Exelixis will split profits and losses associated with the marketing of cobimetinib in America on a sliding scale. If approved outside the U.S., then Exelixis will receive royalties on any cobimetinib sales. 

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may have positions in the companies mentioned. The Motley Fool recommends Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
$19.51 (0.57%) $0.11
Roche Holding AG Stock Quote
Roche Holding AG
$41.57 (-1.68%) $0.71

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.